We hypothesized that TNF-inhibition might block IL-6 creation and create a measurable clinical response in individuals with bone tissue metastases and HRPC. A pilot research was initiated to examine the consequences of TNF-blockade (infliximab, Centocor) in individuals with treatment-refractory HRPC and unpleasant bone tissue metastases. Six individuals with HRPC and unpleasant bone metastases had been… Continue reading We hypothesized that TNF-inhibition might block IL-6 creation and create a